-
Study with
@APassaroMD@matteolambe@weoncologists@curijoey@darioT_ et al quantified commercial tweeting (big pharma & biotech) at a major international conference (#ESMO18). We excluded these tweets to study content of scientific & clinical interest. https://esmoopen.bmj.com/content/5/1/e000598.full?ijkey=Ute5KMvHrA97zOo&keytype=ref …pic.twitter.com/Bas0LCJY1P
-
SOLO-1 results support benefits maintenance olaparib in pts with BRCA mutation.
#LPOEE#ESMO18 pic.twitter.com/bYZbNVXHNK
-
We will be sharing some of the top
#kidneycancer studies of 2018. Here's the first one: our Javelin Renal 101 infographic from#ESMO18.@IKCCorgpic.twitter.com/NAhCIbQlcr
-
Thank you for stressing this!!!! Statement #2 cannot be undervalued!
#ESMO18 study by@neerajaiims nicely showed LOH scores in BRCA2mut vary in different tumor type -
Secondary outcome results of RADICALS trial w med 5 yr F/U: similar PSA recurrence and need for salvage ADT to date, more tox adjuvant
#ESMO18 can’t wait for primary endpoint MFS pic.twitter.com/bjX03DEUGL
-
#ESMO18#LCSM Ready for the amazing Presidential Lung Session! FLAURA and CheckMate 227 the trials that will be present very soon!@myESMO@StephenVLiu@Alfdoc2@Tony_Callespic.twitter.com/v395LNYJN2
-
Great talk on the management of immunotherapy toxicity management
@Dharmisha . Especially helpful for the more complex cases I am starting to see as inpatients.#LPOEE#ESMO18 -
#ESMO19 ready to start!On@Twitter there is just a lot of traffic!Only y-day 1249 tweet with t official#ESMO19 hashtag!#SocialMedia in#Healthcare is growing fast improving medical cultural exchange & snap WW interactions.Coming soon published#ESMO18 twitter analysis.Stay tuned pic.twitter.com/ANwZwFYzSe
-
Clinical Update: Gynae. Dr Lucy Dumas, RMH
#LPOEE#ESMO18 https://www.pscp.tv/w/bw-DWjE0NzQzNjY2fDFZcEtrVmRuellkeGrxqM8juNcqg_TkGd7Hy0-ViXj6x9kdGXysTeo8DY6UVQ== … -
Alpelisib and fulvestrant phase I published in JAMA Oncol! Great timing after presentation of early data from SOLAR-1 at
#ESMO18. Great collaboration with Cornelia Quadt, Dejan Juric,@hoperugo, Jordi Rodon and others. http://ncbi.nlm.nih.gov/pubmed/3054334 … -
Just out in
@FrontOncology the first data of#chemotherapy effect on the ovarian reserve measured by#AMH levels of young#BRCA-mutated#BreastCancer patients: important data to improve the#oncofertility counseling of these women#bcsm#OncoAlert#ESMO18 https://www.frontiersin.org/article/10.3389/fonc.2019.00575 … -
Congrats to
@fperrone62 et al. for publishing the#HOBOE trial (presented at#ESMO18) in#EJC: important data on the role of#OFS plus#AromataseInhibitor#letrozole (with or with#ZoledronicAcid) in premenopausal#BreastCancer patients#OncoAlert#bcsm https://www.ejcancer.com/article/S0959-8049(19)30297-7/fulltext#.XPzQQ3ZustM.twitter … -
@DrCrystalD is leading the GI Med Onc group and GI Cancer Research Program@FoxChaseCancer, Chair@NCCNnews Survivorship Guideline panel, submitted a grant
, poster #ESMO18, received the Rodger Winn award from the NCCN her my work with the organization. /39Prikaži ovu nit -
We have posted over 20 exclusive interviews from
#ESMO18@myESMO click the link below@CaPsurvivorship@charlesryanmd@Daniel_J_George@montypal@PhillipKooMD@PGrivasMDPhD @sgkssg@mdesantis234@TiansterZhang@Tiahigano@mishabeltran@MRHarrisonMD https://www.urotoday.com/video-lectures/esmo-2018.html …pic.twitter.com/VS9knEMaI1
-
Later lines of therapy were not reported, but great question. Agree ORR is low (16% pembro vs 36% chemo). ORR in chemoIO ITT not reported at ASCO (just PDL1+),
@BarbaraBurtness reported ORR of 35.6% for chemoIO at#ESMO18. Patient selection and biomarkers are critical -
Management of Immunotherapy Toxicity. Dharmisha Chauhan, RMH
@Dharmisha#LPOEE#ESMO18 https://www.pscp.tv/w/bw9-BjE0NzQzNjY2fDFqTUpnT1lvdmdPSkxN3BPa7kZ6KtublJwsJkbD6PkVKS0cJeIhv1hy0utrrQ== … -
This past weekend SQZ won best cell therapy poster at
#ESMO#ImmunoOncology Congress. The winning poster described data demonstrating the benefits of the SQZ cell therapy approach over electroporation for modifying immune cells.#ESMO18@myESMOpic.twitter.com/Dh0Qn0pE4E
-
Another excellent session from
@PCaParker at#Esmo18 this morning about current and future radionuclide therapy. Really engaged audience made for great discussion session. Ending my day at conference by mixing it up and seeing what we can learn from pancreatic cancer. -
Will wait to see comparison and more numbers pertaining to longer followup. Previously reported numbers regarding the combination of VEGF

PDL1
#ESMO19 & earlier phase study#ESMO18@myESMO#OncoAlert. Does appear to become an option besides TKIs.#HPBCSM#HepatocellularCancer https://twitter.com/GABOUALFA/status/1186218419433197568 …pic.twitter.com/JwTdS7k2L4
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.